

# Almirall joins the AMR Action Fund to support the fight against antimicrobial resistance

- **Antimicrobial resistance (AMR) is considered one of the most urgent global medical challenges**
- **More than 20 leading biopharmaceutical companies across the globe have raised nearly \$1B of new funding to support clinical research of innovative antibiotics to address this topic**

**Almirall, S.A. (ALM)** has announced today its participation in the AMR Action Fund, a ground-breaking partnership to join forces against antimicrobial resistance (AMR), which aims to bring 2-4 new antibiotics to patients by 2030. The AMR Fund is an initiative of the international body representing the R&D pharmaceutical industry and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). More than 20 biopharmaceutical companies across the globe have raised nearly \$1B new funding to support clinical research of innovative antibiotics to address the most resistant bacteria infections. The Fund will focus on urgent public health needs and will provide much needed financial resources, as well as important technical support to help biotech companies bring novel antibiotics to patients.

Through this new initiative, Almirall will contribute to strengthen and accelerate antibiotic development, focusing on urgent public health needs. Almirall's commitment to improving patients' quality of life means forging ahead with all R&D initiatives coming from different institutions, as R&D is in the DNA of Almirall's identity, developing new and effective treatments.

With this investment from leading biopharmaceutical companies, the AMR Action Fund will be the largest collective venture ever created to address AMR. The AMR Action Fund will invest in innovative antibacterial treatments which make a significant difference in clinical practice. It will also provide technical support to portfolio companies to strengthen antibiotic development and bring together a broad alliance of industry and non-industry stakeholders to create market conditions that enable sustainable investment in the antibiotic pipeline.

## About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel better. We support healthcare professionals in their continuous improvements, providing our innovative solutions where they are needed.

The company was founded over 75 years ago and has its headquarters in Barcelona. It is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key source of value creation for society because of its commitment to its principal shareholders and its mission to help patients by understanding their challenges and using science to provide solutions for real life. Total Revenues in 2019 were more than 900 million euros. Almirall has c. 1,800 employees.

For more information, please visit [almirall.com](https://www.almirall.com)

### Media contact:

Tinkle  
Pilar Colomer  
[pcolomer@tinkle.es](mailto:pcolomer@tinkle.es)  
Phone: (+34) 93 545 12 51

### Corporate Communications contact:

Almirall  
Noel Ortiz  
[noel.ortiz@almirall.com](mailto:noel.ortiz@almirall.com)  
Phone: (+34) 93 291 30 00

### Investors' relations contact:

Almirall  
Pablo Divasson del Fraile  
[pablo.divasson@almirall.com](mailto:pablo.divasson@almirall.com)  
Phone: (+34) 93 291 30 87

### Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate Communication click [here](#)

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: [dpo.global@almirall.com](mailto:dpo.global@almirall.com). PRNewswire is the Agency that licenses your personal data according to their privacy policy <https://gdpr.cision.com/gdpr>. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.